{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 7537,
  "pageSize": 30,
  "pageCount": 10666,
  "rows": [
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 43,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The table displays clinical trial data for NXC-201, specifically focusing on Cytokine Release Syndrome (CRS) and Immune cell associated Neurotoxicity (ICANS) across three dosage groups.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/43",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-43",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 44,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The table highlights specific adverse events (CRS and ICANS) within a red dashed box.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/44",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-44",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 45,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "Highlights NXC-201's lower fludarabine dose (25 mg vs 30 mg) and Carvykti's longer infusion window (5-7 days vs 5 days).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/45",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-45",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 46,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/46",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-46",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 47,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/47",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-47",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 48,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide uses a bar chart to contrast the combined annual sales of two groups of oncology drugs.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/48",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-48",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 49,
      "slideType": "executive_summary",
      "function": "analyze_data",
      "notes": "The slide uses three distinct bar charts to compare IMX-110 performance against standard of care or competitor drugs in preclinical mouse models.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/49",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-49",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 50,
      "slideType": "other",
      "function": "illustrate_case",
      "notes": "Includes a process flow diagram illustrating the mechanism of action of iMX-110 in tumor microenvironments.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/50",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-50",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 51,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "Includes survival curves (Kaplan-Meier style), tumor imaging, and median survival metrics.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/51",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-51",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 52,
      "slideType": "key_takeaways",
      "function": "analyze_data",
      "notes": "Includes clinical trial data visualization with PFS (Progression Free Survival) and PD/PR thresholds.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/52",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-52",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 53,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses a scatter plot to map clinical trials and a table to detail standard-of-care metrics by line of therapy.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/53",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-53",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 54,
      "slideType": "comparison_table",
      "function": "analyze_data",
      "notes": "The slide compares clinical outcomes for patients across different lines of treatment, emphasizing high disease control and zero drug-related toxicity.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/54",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-54",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 55,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "Includes logos for BeiGene and Novartis.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/55",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-55",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 56,
      "slideType": "key_takeaways",
      "function": "present_solution",
      "notes": "Includes comparative size diagram of IMX-111 vs IgG antibody, bar chart of GLUT1 expression by tissue, box plot of GLUT1 expression by stage, and Kaplan-Meier survival curve.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/56",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-56",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 57,
      "slideType": "other",
      "function": "illustrate_case",
      "notes": "Includes two sets of charts: tumor volume line charts and survival curves.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/57",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-57",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 58,
      "slideType": "executive_summary",
      "function": "present_solution",
      "notes": "Includes multiple citations and diagrams of molecular mechanism and clinical trial results.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/58",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-58",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 59,
      "slideType": "peer_benchmark",
      "function": "compare_peers",
      "notes": "The slide compares efficacy data for Humira, Stelara, and Entyvio against their respective placebo groups.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/59",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-59",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 60,
      "slideType": "other",
      "function": "present_solution",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/60",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-60",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 61,
      "slideType": "other",
      "function": "present_solution",
      "notes": "The slide uses a process-flow style layout to connect platform capabilities to specific product outputs.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/61",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-61",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 62,
      "slideType": "other",
      "function": "present_framework",
      "notes": "The process is presented as a non-linear, snake-like flow (1-5 left-to-right, 6-10 right-to-left).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/62",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-62",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 63,
      "slideType": "other",
      "function": "present_solution",
      "notes": "The slide uses a 3-pillar framework to categorize the platform's foundation, leading to specific product applications.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/63",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-63",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "docSlug": "9e6f9592721adb102aeba3d640e068ca",
      "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
      "authorId": "immix-biopharma",
      "authorName": "Immix Biopharma",
      "documentKindSlug": "deck",
      "documentKindLabel": "Deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 64,
      "slideType": "cover",
      "function": "front_matter",
      "notes": "Includes company logo, tagline, mission statement, date, and ticker symbol.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/64",
      "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
      "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-64",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 64,
          "from": 37,
          "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
          "arcName": "The Consultant's Gambit",
          "arcSlug": "consultants-gambit",
          "beatName": "Impact & Next Steps",
          "beatSlug": "consultants-gambit-impact-next-steps",
          "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ac51-70ef-842a-856d8c847de9",
      "docSlug": "98fbb971f05869545d034344ad8adc06",
      "documentTitle": "Independent Bank Corp | Results Presentation Deck | 30 slides",
      "authorId": "independent-bank-corp",
      "authorName": "Independent Bank Corp",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 1,
      "slideType": "cover",
      "function": "front_matter",
      "notes": null,
      "imagePath": "https://imgproxy.kitesheet.com/yjBEf75VAyASFlB3IuOepdIKU3N7m1426T-Jm-p543M/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85OGZiYjk3MWYwNTg2OTU0NWQwMzQzNDRhZDhhZGMwNi9wMDAxLmpwZw",
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ac51-70ef-842a-856d8c847de9/1",
      "deckHref": "/decks/019de076-ac51-70ef-842a-856d8c847de9",
      "deckAnchorHref": "/decks/019de076-ac51-70ef-842a-856d8c847de9#slide-1",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": "https://imgproxy.kitesheet.com/JlMQc66K1_GmaN0cfW5I_jbhEWTcVsuOsNCEXO-Svw8/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85OGZiYjk3MWYwNTg2OTU0NWQwMzQzNDRhZDhhZGMwNi9wMDAxLnBuZw",
      "thumbSrc": "https://imgproxy.kitesheet.com/b-JOvk-8RJAyVm_yLb6hYTyVOPzrAbnww1zNjHKl2TQ/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85OGZiYjk3MWYwNTg2OTU0NWQwMzQzNDRhZDhhZGMwNi9wMDAxLmpwZw",
      "thumbSrcAlt": "https://imgproxy.kitesheet.com/hssJ-estSOYmxyEM3tG3E0kLRopmTKs5obN6FcWA8wg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85OGZiYjk3MWYwNTg2OTU0NWQwMzQzNDRhZDhhZGMwNi9wMDAxLnBuZw"
    },
    {
      "docId": "019de076-ac51-70ef-842a-856d8c847de9",
      "docSlug": "98fbb971f05869545d034344ad8adc06",
      "documentTitle": "Independent Bank Corp | Results Presentation Deck | 30 slides",
      "authorId": "independent-bank-corp",
      "authorName": "Independent Bank Corp",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 2,
      "slideType": "disclaimer",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ac51-70ef-842a-856d8c847de9/2",
      "deckHref": "/decks/019de076-ac51-70ef-842a-856d8c847de9",
      "deckAnchorHref": "/decks/019de076-ac51-70ef-842a-856d8c847de9#slide-2",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ac51-70ef-842a-856d8c847de9",
      "docSlug": "98fbb971f05869545d034344ad8adc06",
      "documentTitle": "Independent Bank Corp | Results Presentation Deck | 30 slides",
      "authorId": "independent-bank-corp",
      "authorName": "Independent Bank Corp",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 3,
      "slideType": "agenda",
      "function": "front_matter",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ac51-70ef-842a-856d8c847de9/3",
      "deckHref": "/decks/019de076-ac51-70ef-842a-856d8c847de9",
      "deckAnchorHref": "/decks/019de076-ac51-70ef-842a-856d8c847de9#slide-3",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ac51-70ef-842a-856d8c847de9",
      "docSlug": "98fbb971f05869545d034344ad8adc06",
      "documentTitle": "Independent Bank Corp | Results Presentation Deck | 30 slides",
      "authorId": "independent-bank-corp",
      "authorName": "Independent Bank Corp",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 4,
      "slideType": "kpi_overview",
      "function": "summarize",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ac51-70ef-842a-856d8c847de9/4",
      "deckHref": "/decks/019de076-ac51-70ef-842a-856d8c847de9",
      "deckAnchorHref": "/decks/019de076-ac51-70ef-842a-856d8c847de9#slide-4",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "cd9f2f95-6638-48d6-9d96-477465ce471a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Problem",
          "beatSlug": "sequoia-pitch-problem",
          "evidence": "Slides 4-9 discuss IBC's Q4 2023 financial performance and challenges.",
          "position": 0,
          "confidence": 0.7,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ac51-70ef-842a-856d8c847de9",
      "docSlug": "98fbb971f05869545d034344ad8adc06",
      "documentTitle": "Independent Bank Corp | Results Presentation Deck | 30 slides",
      "authorId": "independent-bank-corp",
      "authorName": "Independent Bank Corp",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 5,
      "slideType": "kpi_overview",
      "function": "analyze_data",
      "notes": "The slide uses a combination of a donut chart for composition and a combo bar-line chart for cost trends.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ac51-70ef-842a-856d8c847de9/5",
      "deckHref": "/decks/019de076-ac51-70ef-842a-856d8c847de9",
      "deckAnchorHref": "/decks/019de076-ac51-70ef-842a-856d8c847de9#slide-5",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "cd9f2f95-6638-48d6-9d96-477465ce471a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Problem",
          "beatSlug": "sequoia-pitch-problem",
          "evidence": "Slides 4-9 discuss IBC's Q4 2023 financial performance and challenges.",
          "position": 0,
          "confidence": 0.7,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ac51-70ef-842a-856d8c847de9",
      "docSlug": "98fbb971f05869545d034344ad8adc06",
      "documentTitle": "Independent Bank Corp | Results Presentation Deck | 30 slides",
      "authorId": "independent-bank-corp",
      "authorName": "Independent Bank Corp",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 6,
      "slideType": "kpi_overview",
      "function": "analyze_data",
      "notes": "The chart uses a dual-axis approach: left axis for interest rates (percentage), right axis for deposit balances (absolute dollars).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ac51-70ef-842a-856d8c847de9/6",
      "deckHref": "/decks/019de076-ac51-70ef-842a-856d8c847de9",
      "deckAnchorHref": "/decks/019de076-ac51-70ef-842a-856d8c847de9#slide-6",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "cd9f2f95-6638-48d6-9d96-477465ce471a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Problem",
          "beatSlug": "sequoia-pitch-problem",
          "evidence": "Slides 4-9 discuss IBC's Q4 2023 financial performance and challenges.",
          "position": 0,
          "confidence": 0.7,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ac51-70ef-842a-856d8c847de9",
      "docSlug": "98fbb971f05869545d034344ad8adc06",
      "documentTitle": "Independent Bank Corp | Results Presentation Deck | 30 slides",
      "authorId": "independent-bank-corp",
      "authorName": "Independent Bank Corp",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 7,
      "slideType": "kpi_overview",
      "function": "analyze_data",
      "notes": "Includes detailed breakdown of loan origination yields and rate mix (fixed vs variable/indices).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ac51-70ef-842a-856d8c847de9/7",
      "deckHref": "/decks/019de076-ac51-70ef-842a-856d8c847de9",
      "deckAnchorHref": "/decks/019de076-ac51-70ef-842a-856d8c847de9#slide-7",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "cd9f2f95-6638-48d6-9d96-477465ce471a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Problem",
          "beatSlug": "sequoia-pitch-problem",
          "evidence": "Slides 4-9 discuss IBC's Q4 2023 financial performance and challenges.",
          "position": 0,
          "confidence": 0.7,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de076-ac51-70ef-842a-856d8c847de9",
      "docSlug": "98fbb971f05869545d034344ad8adc06",
      "documentTitle": "Independent Bank Corp | Results Presentation Deck | 30 slides",
      "authorId": "independent-bank-corp",
      "authorName": "Independent Bank Corp",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2024-01-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 8,
      "slideType": "kpi_overview",
      "function": "analyze_data",
      "notes": "The slide uses two donut charts to visualize the composition of the portfolio. Data is as of December 31, 2023.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de076-ac51-70ef-842a-856d8c847de9/8",
      "deckHref": "/decks/019de076-ac51-70ef-842a-856d8c847de9",
      "deckAnchorHref": "/decks/019de076-ac51-70ef-842a-856d8c847de9#slide-8",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 9,
          "from": 4,
          "beatId": "cd9f2f95-6638-48d6-9d96-477465ce471a",
          "arcName": "The Sequoia Pitch",
          "arcSlug": "sequoia-pitch",
          "beatName": "Problem",
          "beatSlug": "sequoia-pitch-problem",
          "evidence": "Slides 4-9 discuss IBC's Q4 2023 financial performance and challenges.",
          "position": 0,
          "confidence": 0.7,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}